Oslo, 29 April 2025 - Navamedic ASA (OSE: NAVA) today announced it has signed a
renewed distribution agreement with TopRidge Pharma Limited (TopRidge) for
Imdur®, valid until June 2032, including options for new products to be added
to the agreement.
"It is a pleasure to announce that we have agreed with our great partner
TopRidge Pharma, to revise and renew the distribution agreement for Imdur until
2032. Imdur is our second largest single brand and is currently marketed by us
in the Nordics, the Netherlands, the Baltics, Greece and Cyprus. Although there
is generic competition in this field, the original product is highly valued by
the patients who often stay on the treatment for a long period of time." says
Kathrine Gamborg Andreassen, Chief Executive Officer of Navamedic.
Imdur® (isosorbide mononitrate), is a prescription medication used to prevent
angina pectoris due to heart disease. It was first launched in Europe in 1985.
Navamedic commenced distribution of the product as part of a strategic
partnership and long-term distribution agreement with TopRidge Pharma Limited in
2016.
"Imdur® remains an important product to Navamedic, and we appreciate the efforts
made by TopRidge to update the Marketing Authorisations and to secure steady
supplies to our markets. With the renewal of this agreement, we look forward to
exploring further collaboration opportunities for additional products in the
future," Gamborg Andreassen concludes.
The effective date of the agreement is 1 January 2025, and the revised terms of
the agreement are implemented from this date even though the signature date is
29 April 2025.
For further information, please contact:
Kathrine Gamborg Andreassen, CEO, Navamedic
Mobile: +47 951 78 680
E-mail: kathrine@navamedic.com
Lars Hjarrand, CFO, Navamedic
Mobile: +47917 62 842
E-mail: lars.hjarrand@navamedic.com
About Navamedic
Navamedic ASA is a Nordic pharmaceutical company dedicated to enhancing people's
quality of life by being a reliable supplier of high-quality prescription,
consumer health, and hospital products to hospitals and pharmacies. Our growing
product portfolio has been carefully selected to meet current public health
concerns, such as obesity, Parkinson's disease, antibiotics and metabolism, to
empower people to live healthier and more fulfilling lives.
What sets us apart is our deep-rooted commitment to understanding the needs and
requirements of the countries where we are present. Our local insight and
competence enable us to understand the specific needs of each country where we
operate and ultimately to gain market access. This makes us a preferred partner
for international companies expanding their footprint across the Nordics and
Benelux regions, through either in-licensing or out-licensing. Navamedic has
been listed on the Oslo Stock Exchange since 2006 (ticker: NAVA) and is
headquartered in Oslo, Norway.
For more information, please visit Navamedic.com.
This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.